|
Fractionated
stereotactic radiosurgery and concurrent taxol in recurrent glioblastoma
multiforme: a preliminary report
Lederman G, Arbit E, Odaimi M, Lombardi E, Wrzolek M,
Wronski M
Department
of Radiation Oncology, Staten Island University Hospital, NY 10305, USA.
gillederman@compuserve.com
Purpose.
Surgery and systemic chemotherapy offer modest benefit to patients with
recurrent glioblastoma multiforme. These tumors are associated with rapid growth
and progressive neurological deterioration.
Radiosurgery offers a rational alternative treatment, delivering intensive local
therapy.
A pilot protocol to treat recurrent glioblastoma was developed using
fractionated stereotactic radiosurgery with concurrent intravenous (i.v.) Taxol
as a radiation sensitizer.
Methods
and Materials. The treatment outcome was analyzed in 14 patients with recurrent
glioblastoma treated with fractionated stereotactic radiosurgery and concurrent
Taxol.
Median tumor volume was 15.7 cc and patients received a mean radiation dose of
6.2 Gy at 90% isodose line, 4 times weekly.
The median dose of Taxol was 120 mg/m2.
Results.
The median survival was 14.2 months, 1-year survival was 50%.
Conclusions.
Survival for this small group of patients was similar to or better than
historical controls or patients treated with single-fraction radiosurgery alone.
This data should stimulate the investigation of both fractionated radiosurgery
and the development of radiation sensitizers to further enhance treatment.
PMID:
9486617 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9486617&dopt=Abstract |
